Abstract: A drive unit for an electrical power-assisted steering system of a motor vehicle may include an electric motor with a stator housing to which a control housing, in which a control circuit board is arranged, is attached, and with a connecting unit, attached to the stator housing, which has electrical connecting elements and at least one positioning element. The connecting elements are electrically connected to the electric motor and to the control circuit board. The positioning element interacts with the control circuit board for the purpose of relative positioning. To enable simpler and more secure mounting, the positioning element interacts with the control housing for the purpose of relative positioning.

Abstract: A method for controlling a servomotor with a converter includes monitoring a circuit of a direct-voltage DC link that is connected to an input circuit for flow of an electric current; switching off a first switching device to end the supply of the direct-voltage DC link from an electrical grid if a stop signal occurs; braking the servomotor by control of power semiconductor switches of an inverter circuit in a regenerative braking operation, to reduce the rotation speed of the servomotor, if the monitoring detects that an electric current is not flowing after the first switching device has been switched off; and switching off a second switching device to prevent feeding electrical energy from the direct-voltage DC link into the servomotor if the monitoring detects a flow of electric current after the first switching device has been switched off.

Abstract: The present disclosure provides methods for treating sarcoidosis-associated pulmonary hypertension, comprising administering to a patient in need thereof, a therapeutically effective amount of selexipag, wherein the patient is diagnosed with sarcoidosis-associated pulmonary hypertension.

Abstract: This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibody responses in a vaccinated subject. The invention further provides a method for prevention or treatment of a disease by inducing hapten-specific antibodies in a subject comprising administering into said subject a composition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto.

Abstract: This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibody responses in a vaccinated subject. The invention further provides a method for prevention or treatment of a disease by inducing hapten-specific antibodies in a subject comprising administering into said subject a composition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto.

Abstract: The present invention relates to a parenteral composition comprising a bisphosphonic acid or a pharmaceutically acceptable salt thereof (bisphosphonate) as active component and a pharmaceutically acceptable chelating agent, processes of the preparation of this composition, and methods of their use in the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease. The compositions are especially useful for improving the local tolerance of the active component when administered parenterally.

Abstract: The present invention relates to a parenteral composition comprising a bisphosphonic acid or a pharmaceutically acceptable salt thereof (bisphosphonate) as active component and a pharmaceutically acceptable chelating agent, processes of the preparation of this composition, and methods of their use in the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease. The compositions are especially useful for improving the local tolerance of the active component when administered parenterally.